Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Evolent Health (EVH) but lowers the price target from $44 to $41.

May 10, 2024 | 6:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Evolent Health but reduces the price target from $44 to $41.
While the reduction in price target could suggest a slightly less optimistic outlook on EVH's future price performance, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to a neutral short-term impact on EVH's stock price as investors weigh the lowered price target against the reaffirmed positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100